Parkinson's disease progresses to stages where oral treatments become insufficient. While continuous subcutaneous foslevodopa/foscarbidopa (fLD/fCD), a less invasive option, improves motor control, yet little is known about patients and caregivers experiences. This phenomenological study explores these perspectives in Quebec to inform better support, adherence and quality of life.
Parkinson's disease progresses to stages where oral treatments become insufficient. While continuous subcutaneous foslevodopa/foscarbidopa (fLD/fCD), a less invasive option, improves motor control, yet little is known about patients and caregivers experiences. This phenomenological study explores these perspectives in Quebec to inform better support, adherence and quality of life.
Ballroom CANNmore2026- 57th Annual Meeting and Scientific Sessions conference@cann.ca
Technical Issues?
If you're experiencing playback problems, try adjusting the quality or refreshing the page.
Questions for Speakers?
Use the Q&A tab to submit questions that may be addressed in follow-up sessions.
